This page shows the publications co-authored by Rebecca Heist and Michael Lanuti.
The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. J Thorac Oncol. 2014 Sep; 9(9):1363-9.
The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers. Ann Thorac Surg. 2013 Sep; 96(3):962-8.
Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. Clin Cancer Res. 2021 12 01; 27(23):6343-6353.
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. J Clin Oncol. 2019 01 10; 37(2):97-104.
Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy. Int J Radiat Oncol Biol Phys. 2017 May 01; 98(1):220.
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011 Dec; 22(12):2616-2624.
SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice. J Clin Oncol. 2011 May 20; 29(15_suppl):7518.
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011 Mar 23; 3(75):75ra26.
Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma risk. Carcinogenesis. 2009 Aug; 30(8):1363-7.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.